- Home
- CHRS vs SPKL Comparison
CHRS vs SPKL Comparison
Compare CHRS & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SPKL
- Stock Information
- Founded
- CHRS 2010
- SPKL 2021
- Country
- CHRS United States
- SPKL United States
- Employees
- CHRS 235
- SPKL N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SPKL
- Sector
- CHRS Health Care
- SPKL
- Exchange
- CHRS Nasdaq
- SPKL Nasdaq
- Market Cap
- CHRS 134.4M
- SPKL 175.4M
- IPO Year
- CHRS 2014
- SPKL 2023
- Fundamental
- Price
- CHRS $1.16
- SPKL $10.69
- Analyst Decision
- CHRS Strong Buy
- SPKL
- Analyst Count
- CHRS 4
- SPKL 0
- Target Price
- CHRS $5.38
- SPKL N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- SPKL 22.9K
- Earning Date
- CHRS 03-12-2025
- SPKL 01-01-0001
- Dividend Yield
- CHRS N/A
- SPKL N/A
- EPS Growth
- CHRS N/A
- SPKL N/A
- EPS
- CHRS N/A
- SPKL 0.19
- Revenue
- CHRS $304,340,000.00
- SPKL N/A
- Revenue This Year
- CHRS $2.47
- SPKL N/A
- Revenue Next Year
- CHRS N/A
- SPKL N/A
- P/E Ratio
- CHRS N/A
- SPKL $57.72
- Revenue Growth
- CHRS 44.19
- SPKL N/A
- 52 Week Low
- CHRS $0.66
- SPKL $10.20
- 52 Week High
- CHRS $2.87
- SPKL $11.95
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- SPKL 61.23
- Support Level
- CHRS $1.03
- SPKL $10.63
- Resistance Level
- CHRS $1.39
- SPKL $10.70
- Average True Range (ATR)
- CHRS 0.14
- SPKL 0.01
- MACD
- CHRS -0.03
- SPKL -0.00
- Stochastic Oscillator
- CHRS 14.04
- SPKL 65.62
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.